# Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

> **NCT01381757** · — · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 34 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- Mycobacterium Tuberculous
- Antitubercular Agents
- Tuberculosis, Mulutidrug-Resistant
- Extensively Drug-Resistant
- Extensibely Drug-Resistant Tuberculosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01381757
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05-31
- **Primary completion:** —
- **Final completion:** 2013-03-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381757, "Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01381757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*